Hansoh Pharma Inks $203M Deal for HIF-2α Inhibitor NKT2152 to Target ccRCC in Greater China

On May 3, Hansoh Pharmaceutical Group Company Limited announced that its wholly-owned subsidiaries, Hansoh (Shanghai) Health and Jiangsu Hansoh Pharma (collectively referred to as the "Licensees"), entered into an exclusive license agreement with NiKang Therapeutics, Inc.

According to the license agreement, the licensee has obtained an exclusive license from NiKang Therapeutics to develop and commercialize NKT2152 for cancer treatment in China (including Hong Kong, Macao, and Taiwan). The licensee will be responsible for the development, regulatory approval, and commercialization of NKT2152 in China. Additionally, the licensee will pay a $15 million upfront payment, up to $203 million in potential development, regulatory, and sales-based commercial milestone payments, as well as tiered royalties based on net sales.

NKT2152 is a small molecule inhibitor of HIF-2α currently under investigation in a Phase I/II dose escalation and expansion trial (NCT05119335). The trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity in patients with advanced clear cell renal cell carcinoma (ccRCC).